Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRA · 1 trial · 1 indication
AUC 0-24 of PRA when taken with SCY-078.
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Single oral 20-mg dose of PRA on Day 1 AM |
| Treatment B | EXPERIMENTAL | Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later. |
| Name | Type | Description |
|---|---|---|
| PRA | DRUG | Single oral 20-mg dose of PRA on Day 1 AM |
| SCY-078 plus PRA | DRUG | Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later |
Inclusion Criteria: 1. is a male or female between 18 to 55 years, inclusive, of age at the prestudy (screening) visit (time of signing the Informed Consent). 2. has a Body Mass Index (BMI) 18.0 to 32 kg/m2 at the prestudy (screening) visit. 3. is judged to be in good health based on medical histor...
PRA is an internal shorthand used by SCYNEXIS, Inc. for pravastatin, a small molecule drug that was studied as a comparator in a Phase 1 pharmacokinetic trial. The trial examined how another SCYNEXIS compound affects the way the body processes pravastatin in healthy volunteers.
PRA is not a SCYNEXIS development asset. SCYNEXIS, Inc., which trades on the Nasdaq under the ticker SCYX, used pravastatin as a probe drug in a drug-drug interaction study. Pravastatin itself is a widely available generic medicine, and SCYNEXIS does not develop or commercialize it.
PRA was used in a single completed Phase 1 trial sponsored by SCYNEXIS, Inc. That study enrolled 28 healthy adult volunteers in Australia and has finished. PRA is not an investigational new drug in SCYNEXIS's pipeline; it served as a comparator to measure pharmacokinetic interactions.
PRA appears in one completed trial, NCT04092751, titled Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects. It was a Phase 1, randomized, controlled study with 28 enrolled participants, conducted in Australia in healthy volunteers aged 18 years and older.
Yes. PRA is shorthand for pravastatin, the small molecule statin used in SCYNEXIS's Phase 1 drug-drug interaction study. In trial NCT04092751, pravastatin was given to healthy volunteers to assess whether SCY-078 (ibrexafungerp) changes its pharmacokinetics.